Studying the effect of Amalaki Raskriya Anjana in the treatment of Blepharitis (Eyelid Inflammation)

Randomized controlled clinical trial to determine the effect of Amalaki (Emblica officinalis) Raskriya Anjana in the management of Klinna Vartma w.s.r to Blepharitis - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086512

Enrollment

Registered

2025-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H010- Blepharitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient who are suffering from symptoms and signs of Klinna Vartma as mentioned below, symptoms- Itching(kandu),lacrimation,eyelid edema (shotha), redness of lid margin signs - falling of eyelashes 2. Age between 18 to 60 years. 3. Patients of either Gender, irrespective of socioeconomic status. 4. Patient willing to sign the informed consent form. 5. Patient fit for the Anjana karma.

Exclusion criteria

Exclusion criteria: 1. Known case of Hypertension, Diabetes Mellitus,AIDS, Malignancies etc. 2. Patient on any other systemic treatment. 3. Patient having any other ocular pathology. 4. Ulcerative Blepharitis.

Design outcomes

Primary

Measure	Time frame
Clinical improvement in blepharitis symptomsTimepoint: From 7-14 days after administration of Anjana	—

Secondary

Measure	Time frame
Reduction in recurrence rate, Change in quality of life related to eye comfortTimepoint: From 14-28 days after administration of Anjana	—

Countries

India

Contacts

Public ContactDr Rekha Jori

SST Ayurved College

drrekhamatkar1912@gmail.com9503197787

Outcome results